Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Amortizatization of Intangibles: 2023-2025

Historic Amortizatization of Intangibles for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $1,000.

  • Contineum Therapeutics' Amortizatization of Intangibles fell 99.87% to $1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 56.84%. This contributed to the annual value of $3.9 million for FY2024, which is 47.29% up from last year.
  • Contineum Therapeutics' Amortizatization of Intangibles amounted to $1,000 in Q3 2025, which was down 99.75% from $407,000 recorded in Q2 2025.
  • Contineum Therapeutics' Amortizatization of Intangibles' 5-year high stood at $1.2 million during Q4 2023, with a 5-year trough of $1,000 in Q3 2025.
  • Over the past 3 years, Contineum Therapeutics' median Amortizatization of Intangibles value was $783,000 (recorded in 2024), while the average stood at $664,364.
  • In the last 5 years, Contineum Therapeutics' Amortizatization of Intangibles spiked by 388.13% in 2024 and then tumbled by 99.87% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $1.2 million in 2023, then fell by 11.10% to $1.1 million in 2024, then slumped by 99.87% to $1,000 in 2025.
  • Its Amortizatization of Intangibles stands at $1,000 for Q3 2025, versus $407,000 for Q2 2025 and $285,000 for Q1 2025.